Rezolute, Inc. - Common Stock (NV) (RZLT)
5.1000
-0.4700 (-8.44%)
Rezolute Inc is a biopharmaceutical company focused on developing innovative therapies to address serious diseases and unmet medical needs, particularly in the fields of metabolic and ocular disorders
The company's research is aimed at advancing its proprietary drug candidates through clinical development to improve patient outcomes. By leveraging advanced scientific insights and novel technologies, Rezolute seeks to create impactful treatment options for conditions that currently have limited or no effective therapies, thereby contributing to the advancement of healthcare solutions.
![](https://cdn.benzinga.com/files/images/story/2024/09/09/Health-And-Longevity.jpeg?width=1200&height=800&fit=crop)
FDA lifts clinical hold on Rezolute's RZ358 for treating congenital hyperinsulinism, allowing U.S. participants in Phase 3 study. Enrollment expected to start in 2025 with topline data by mid-year.
Via Benzinga · September 9, 2024
![](https://cdn.benzinga.com/files/images/story/2024/06/14/movers-image_24.jpeg?width=1200&height=800&fit=crop)
Via Benzinga · June 14, 2024
![](https://investorplace.com/wp-content/uploads/2022/05/earnings-season-1600.png)
RZLT stock results show that Rezolute missed analyst estimates for earnings per share the third quarter of 2024.
Via InvestorPlace · May 15, 2024
![](https://cdn.benzinga.com/files/images/story/2024/06/14/movers-image_7.jpeg?width=1200&height=800&fit=crop)
Via Benzinga · June 14, 2024
![](https://cdn.benzinga.com/files/images/story/2023/movers_image_0.jpeg?width=1200&height=800&fit=crop)
Via Benzinga · June 14, 2024
![](https://investorplace.com/wp-content/uploads/2021/04/wall-street.jpg)
Pre-market stock movers are worth checking out on Friday as we dive into all of the biggest news moving shares this morning!
Via InvestorPlace · June 14, 2024
![](https://cdn.benzinga.com/files/images/story/2024/06/14/Adobe.jpeg?width=1200&height=800&fit=crop)
Via Benzinga · June 14, 2024
![](https://cdn.benzinga.com/files/images/story/2024/06/14/xrdDAFekDI-j282-j1745615867-t23032908.jpeg?width=1200&height=800&fit=crop)
Via Benzinga · June 14, 2024
![](https://cdn.benzinga.com/files/images/story/2023/movers_image_1.jpeg?width=1200&height=800&fit=crop)
Via Benzinga · June 13, 2024
![](https://cdn.benzinga.com/files/images/story/2023/movers_image_18.jpeg?width=1200&height=800&fit=crop)
Via Benzinga · June 12, 2024
![](https://cdn.benzinga.com/files/images/story/2023/movers_image_5.jpeg?width=1200&height=800&fit=crop)
Via Benzinga · June 7, 2024
![](https://cdn.benzinga.com/files/images/story/2023/movers_image_5.jpeg?width=1200&height=800&fit=crop)
Via Benzinga · June 5, 2024
![](https://cdn.benzinga.com/files/images/story/2024/05/22/xrdDAFj0FUZspA2-j5351515556-t23052408.jpeg?width=1200&height=800&fit=crop)
Via Benzinga · May 22, 2024
![](https://cdn.benzinga.com/files/images/story/2023/movers_image_1.jpeg?width=1200&height=800&fit=crop)
Via Benzinga · May 22, 2024
![](https://cdn.benzinga.com/files/images/story/2024/05/22/RZLT.png?width=1200&height=800&fit=crop)
Rezolute announced topline results from the Phase 2 study of RZ402 for diabetic macular edema, showing significant improvements in macular edema and a favorable safety profile.
Via Benzinga · May 22, 2024
![](https://investorplace.com/wp-content/uploads/2021/04/wall-street-washington-statue.jpg)
Pre-market stock movers are worth checking out on Wednesday as we offer up all the latest news sending shares higher and lower this morning!
Via InvestorPlace · May 22, 2024
![](https://cdn.benzinga.com/files/images/story/2023/movers_image_0.jpeg?width=1200&height=800&fit=crop)
Via Benzinga · May 21, 2024
![](https://cdn.benzinga.com/files/images/story/2023/movers_image_5.jpeg?width=1200&height=800&fit=crop)
Via Benzinga · April 23, 2024
![](https://investorplace.com/wp-content/uploads/2022/06/biotechnologyepzm1600.png)
Discover three biotech stocks with explosive growth potential. Don't miss out on these great picks this year.
Via InvestorPlace · April 15, 2024
![](/next-assets/images/schema-image-default.png)
The Dow Jones index closed higher by around 0.1% on Thursday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.
Via Benzinga · April 1, 2024
![](https://cdn.benzinga.com/files/images/story/2024/03/20/image33.jpeg?width=1200&height=800&fit=crop)
The Dow Jones index closed higher by over 300 points on Tuesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.
Via Benzinga · March 20, 2024
![](https://cdn.benzinga.com/files/images/story/2024/03/11/image45.jpg?width=1200&height=800&fit=crop)
The Dow Jones index closed lower by around 0.2% on Friday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.
Via Benzinga · March 11, 2024
![](https://cdn.benzinga.com/files/images/story/2024/02/28/image24.jpeg?width=1200&height=800&fit=crop)
The Dow Jones index closed lower by around 100 points on Tuesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.
Via Benzinga · February 28, 2024
![](https://cdn.benzinga.com/files/images/story/2024/02/22/image20.jpg?width=1200&height=800&fit=crop)
The Dow Jones index closed higher by around 0.1% on Wednesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.
Via Benzinga · February 22, 2024